Seth Rudnick, M.D., joined Canaan in 1998 as a Venture Partner focusing on Health Care Investments. He became a General Partner in the firm in 2000. His background in the health care industry includes comprehensive experience in research, development, clinical trials analysis and biotechnology, as well as founding and growing start-up companies in the industry. Dr. Rudnick currently also serves on the Board of Diectors of Genaissance, CombinatoRx, Immunicon, Phylogix, Pintex, Spine Wave, Vertis and several other private companies. Prior to joining Canaan, Dr. Rudnick had served as CEO and Chairman at CytoTherapeutics. Before that he helped found and served as head of R&D for Ortho Biotech, a division of Johnson & Johnson. In that role, he led development efforts for a portfolio of projects whose worldwide revenues now exceed $1 billion in annual sales. He began his industrial career at Schering-Plough where he ran clinical trials for the alpha interferon project, and later transferred to Biogen to run that company�s pharmaceutical development efforts. His academic career began when he served on the medical and public health faculty at the University of North Carolina at Chapel Hill. Seth is a Clinical Professor of Medicine at Chapel Hill where he advised the faculty on biotechnology issues.